Standard Chartered has committed $1bn in financing for companies that provide goods and services to help the fight against coronavirus (Covid-19).

The bank intends to finance the service providers and companies manufacturing ventilators, masks, protective equipment, sanitizers, and other consumables.

These companies include manufacturers and distributors in the pharmaceutical industry, healthcare providers and non-medical companies.

Standard Chartered corporate, commercial and institutional banking CEO Simon Cooper said: “Clearly there’s a cost for companies to switch into these hugely in-demand items, so it’s an area where we can help them get up and running more quickly.

“At the same time, we want to make sure that existing manufacturers and service providers get the support they need.”

The bank will provide the financing in the form of loans at preferential rates, import/export finance or the working capital facilities that they use for day-to-day business operations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The financing will also be made available to companies that have switched into making high demand products to tackle the pandemic.

The bank noted that it is currently identifying such companies that have decided to start manufacturing anti-virus products.

Cooper added: “Our industry teams are looking across our client base and, given our understanding of clients’ current manufacturing processes; we’re assessing which companies might want to consider adding these items to their production line.”

The financing is subject to the receipt of regulatory approvals to manufacture the goods.